Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products. Founded in 2006, headquartered in Santa Barbara, United States. The company has raised $51.8M in funding at the series b stage. T The company operates in Life Sciences > Genomics, Life Sciences > Clinical Genomics, Life Sciences > Infectious Diseases, Sustainability Tech > Infectious Diseases. Its business models include Infectious Diseases > In Vitro Diagnostic Tests > Bacterial, Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Infectious Diseases. Founded in 2006. Headquartered in United States, Santa Barbara. The company has raised funding at the Series B stage. Backed by investors including National Science Foundation.
Affinity Biosensors
Series BDeveloper of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products. Founded in 2006, headquartered in Santa Barbara,…
About
Business model
Infectious Diseases > In Vitro Diagnostic Tests > Bacterial,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Infectious Diseases
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.